Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.63 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21991262 | 0.92 | ALDH1A1 (0.53) | MAOBPPARGMEN1KMT2APPARA | |
| SCHEMBL18002977 | 0.89 | MAOB (0.63) | MAOBFFAR1SLC6A5PPARGPPARA | |
| SCHEMBL21992617 | 0.87 | LTA4H (0.49) | MAOBPPARGMEN1KMT2APPARA | |
| SCHEMBL21991530 | 0.87 | MAOB (0.60) | MAOBFFAR1SLC6A5PPARGHRH3 | |
| SCHEMBL23605765 | 0.86 | MAOB (0.66) | MAOBFFAR1SLC6A5PPARGHRH3 | |
| SCHEMBL13280077 | 0.86 | MAOB (0.66) | MAOBFFAR1SLC6A5PPARGHRH3 | |
| SCHEMBL21991287 | 0.86 | MAOB (0.59) | MAOBFFAR1SLC6A5PPARGHRH3 | |
| SCHEMBL21991284 | 0.85 | MAOB (0.63) | MAOBFFAR1PPARGHRH3PPARA | |
| SCHEMBL21992633 | 0.82 | MAOB (0.60) | MAOBKMT2A | |
| SCHEMBL21991493 | 0.81 | MAOB (0.66) | MAOBFFAR1SLC6A5PPARGHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | MAOB 3946/4885FFAR1 147/4885SLC6A5 837/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | MAOB 3946/4885FFAR1 147/4885SLC6A5 837/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | MAOB 3946/4885FFAR1 147/4885SLC6A5 837/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | MAOB 3946/4885FFAR1 147/4885SLC6A5 837/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | MAOB 3946/4885FFAR1 147/4885SLC6A5 837/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | MAOB 3946/4885FFAR1 147/4885SLC6A5 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.